Found 6 hits Enz. Inhib. hit(s) with Target = 'Toll-like receptor 7' and Ligand = 'BDBM427911' Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Toll-like receptor 7
(Homo sapiens (Human)) | BDBM427911
![PNG](/data/jpeg/tenK42/BindingDB_427911.png) (US10544143, Example 345 | US10544143, Example 346 ...)Show SMILES COc1cc(cn2ncnc12)-c1[nH]c2cc(F)c(nc2c1C(C)C)C1CCC(CC1)NC1COC1 |(9.81,1.98,;8.27,1.98,;7.5,.65,;5.96,.65,;5.19,-.69,;5.96,-2.02,;7.5,-2.02,;8.53,-3.16,;9.94,-2.54,;9.78,-1.01,;8.27,-.69,;3.65,-.69,;2.75,-1.93,;1.28,-1.46,;-.05,-2.23,;-1.39,-1.46,;-2.72,-2.23,;-1.39,.08,;-.05,.85,;1.28,.08,;2.75,.56,;3.15,2.05,;2.06,3.14,;4.63,2.45,;-2.72,.85,;-4.05,.08,;-5.39,.85,;-5.39,2.39,;-4.05,3.16,;-2.72,2.39,;-6.72,3.16,;-8.05,2.39,;-9.54,2.79,;-9.94,1.31,;-8.45,.91,)| Show InChI InChI=1S/C26H31FN6O2/c1-14(2)22-24(16-8-21(34-3)26-28-13-29-33(26)10-16)31-20-9-19(27)23(32-25(20)22)15-4-6-17(7-5-15)30-18-11-35-12-18/h8-10,13-15,17-18,30-31H,4-7,11-12H2,1-3H3 | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.210 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description HEK-Blue-cells (Invivogen) overexpressing human TLR7, TLR8 or TLR9 receptors were used for screening inhibitors of these receptors using an inducible... |
US Patent US10544143 (2020)
BindingDB Entry DOI: 10.7270/Q2QF8W80 |
More data for this Ligand-Target Pair | |
Toll-like receptor 7
(Homo sapiens (Human)) | BDBM427911
![PNG](/data/jpeg/tenK42/BindingDB_427911.png) (US10544143, Example 345 | US10544143, Example 346 ...)Show SMILES COc1cc(cn2ncnc12)-c1[nH]c2cc(F)c(nc2c1C(C)C)C1CCC(CC1)NC1COC1 |(9.81,1.98,;8.27,1.98,;7.5,.65,;5.96,.65,;5.19,-.69,;5.96,-2.02,;7.5,-2.02,;8.53,-3.16,;9.94,-2.54,;9.78,-1.01,;8.27,-.69,;3.65,-.69,;2.75,-1.93,;1.28,-1.46,;-.05,-2.23,;-1.39,-1.46,;-2.72,-2.23,;-1.39,.08,;-.05,.85,;1.28,.08,;2.75,.56,;3.15,2.05,;2.06,3.14,;4.63,2.45,;-2.72,.85,;-4.05,.08,;-5.39,.85,;-5.39,2.39,;-4.05,3.16,;-2.72,2.39,;-6.72,3.16,;-8.05,2.39,;-9.54,2.79,;-9.94,1.31,;-8.45,.91,)| Show InChI InChI=1S/C26H31FN6O2/c1-14(2)22-24(16-8-21(34-3)26-28-13-29-33(26)10-16)31-20-9-19(27)23(32-25(20)22)15-4-6-17(7-5-15)30-18-11-35-12-18/h8-10,13-15,17-18,30-31H,4-7,11-12H2,1-3H3 | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.210 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description HEK-Blue-cells (Invivogen) overexpressing human TLR7, TLR8 or TLR9 receptors were used for screening inhibitors of these receptors using an inducible... |
US Patent US10730877 (2020)
BindingDB Entry DOI: 10.7270/Q2H41VH3 |
More data for this Ligand-Target Pair | |
Toll-like receptor 7
(Homo sapiens (Human)) | BDBM427911
![PNG](/data/jpeg/tenK42/BindingDB_427911.png) (US10544143, Example 345 | US10544143, Example 346 ...)Show SMILES COc1cc(cn2ncnc12)-c1[nH]c2cc(F)c(nc2c1C(C)C)C1CCC(CC1)NC1COC1 |(9.81,1.98,;8.27,1.98,;7.5,.65,;5.96,.65,;5.19,-.69,;5.96,-2.02,;7.5,-2.02,;8.53,-3.16,;9.94,-2.54,;9.78,-1.01,;8.27,-.69,;3.65,-.69,;2.75,-1.93,;1.28,-1.46,;-.05,-2.23,;-1.39,-1.46,;-2.72,-2.23,;-1.39,.08,;-.05,.85,;1.28,.08,;2.75,.56,;3.15,2.05,;2.06,3.14,;4.63,2.45,;-2.72,.85,;-4.05,.08,;-5.39,.85,;-5.39,2.39,;-4.05,3.16,;-2.72,2.39,;-6.72,3.16,;-8.05,2.39,;-9.54,2.79,;-9.94,1.31,;-8.45,.91,)| Show InChI InChI=1S/C26H31FN6O2/c1-14(2)22-24(16-8-21(34-3)26-28-13-29-33(26)10-16)31-20-9-19(27)23(32-25(20)22)15-4-6-17(7-5-15)30-18-11-35-12-18/h8-10,13-15,17-18,30-31H,4-7,11-12H2,1-3H3 | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.210 | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| Assay Description HEK-Blue™-cells (Invivogen) overexpressing human TLR7, TLR8 or TLR9 receptors were used for screening inhibitors of these receptors using an inducibl... |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2S46W4Z |
More data for this Ligand-Target Pair | |
Toll-like receptor 7
(Homo sapiens (Human)) | BDBM427911
![PNG](/data/jpeg/tenK42/BindingDB_427911.png) (US10544143, Example 345 | US10544143, Example 346 ...)Show SMILES COc1cc(cn2ncnc12)-c1[nH]c2cc(F)c(nc2c1C(C)C)C1CCC(CC1)NC1COC1 |(9.81,1.98,;8.27,1.98,;7.5,.65,;5.96,.65,;5.19,-.69,;5.96,-2.02,;7.5,-2.02,;8.53,-3.16,;9.94,-2.54,;9.78,-1.01,;8.27,-.69,;3.65,-.69,;2.75,-1.93,;1.28,-1.46,;-.05,-2.23,;-1.39,-1.46,;-2.72,-2.23,;-1.39,.08,;-.05,.85,;1.28,.08,;2.75,.56,;3.15,2.05,;2.06,3.14,;4.63,2.45,;-2.72,.85,;-4.05,.08,;-5.39,.85,;-5.39,2.39,;-4.05,3.16,;-2.72,2.39,;-6.72,3.16,;-8.05,2.39,;-9.54,2.79,;-9.94,1.31,;-8.45,.91,)| Show InChI InChI=1S/C26H31FN6O2/c1-14(2)22-24(16-8-21(34-3)26-28-13-29-33(26)10-16)31-20-9-19(27)23(32-25(20)22)15-4-6-17(7-5-15)30-18-11-35-12-18/h8-10,13-15,17-18,30-31H,4-7,11-12H2,1-3H3 | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.320 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description HEK-Blue-cells (Invivogen) overexpressing human TLR7, TLR8 or TLR9 receptors were used for screening inhibitors of these receptors using an inducible... |
US Patent US10730877 (2020)
BindingDB Entry DOI: 10.7270/Q2H41VH3 |
More data for this Ligand-Target Pair | |
Toll-like receptor 7
(Homo sapiens (Human)) | BDBM427911
![PNG](/data/jpeg/tenK42/BindingDB_427911.png) (US10544143, Example 345 | US10544143, Example 346 ...)Show SMILES COc1cc(cn2ncnc12)-c1[nH]c2cc(F)c(nc2c1C(C)C)C1CCC(CC1)NC1COC1 |(9.81,1.98,;8.27,1.98,;7.5,.65,;5.96,.65,;5.19,-.69,;5.96,-2.02,;7.5,-2.02,;8.53,-3.16,;9.94,-2.54,;9.78,-1.01,;8.27,-.69,;3.65,-.69,;2.75,-1.93,;1.28,-1.46,;-.05,-2.23,;-1.39,-1.46,;-2.72,-2.23,;-1.39,.08,;-.05,.85,;1.28,.08,;2.75,.56,;3.15,2.05,;2.06,3.14,;4.63,2.45,;-2.72,.85,;-4.05,.08,;-5.39,.85,;-5.39,2.39,;-4.05,3.16,;-2.72,2.39,;-6.72,3.16,;-8.05,2.39,;-9.54,2.79,;-9.94,1.31,;-8.45,.91,)| Show InChI InChI=1S/C26H31FN6O2/c1-14(2)22-24(16-8-21(34-3)26-28-13-29-33(26)10-16)31-20-9-19(27)23(32-25(20)22)15-4-6-17(7-5-15)30-18-11-35-12-18/h8-10,13-15,17-18,30-31H,4-7,11-12H2,1-3H3 | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.320 | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| Assay Description HEK-Blue™-cells (Invivogen) overexpressing human TLR7, TLR8 or TLR9 receptors were used for screening inhibitors of these receptors using an inducibl... |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2S46W4Z |
More data for this Ligand-Target Pair | |
Toll-like receptor 7
(Homo sapiens (Human)) | BDBM427911
![PNG](/data/jpeg/tenK42/BindingDB_427911.png) (US10544143, Example 345 | US10544143, Example 346 ...)Show SMILES COc1cc(cn2ncnc12)-c1[nH]c2cc(F)c(nc2c1C(C)C)C1CCC(CC1)NC1COC1 |(9.81,1.98,;8.27,1.98,;7.5,.65,;5.96,.65,;5.19,-.69,;5.96,-2.02,;7.5,-2.02,;8.53,-3.16,;9.94,-2.54,;9.78,-1.01,;8.27,-.69,;3.65,-.69,;2.75,-1.93,;1.28,-1.46,;-.05,-2.23,;-1.39,-1.46,;-2.72,-2.23,;-1.39,.08,;-.05,.85,;1.28,.08,;2.75,.56,;3.15,2.05,;2.06,3.14,;4.63,2.45,;-2.72,.85,;-4.05,.08,;-5.39,.85,;-5.39,2.39,;-4.05,3.16,;-2.72,2.39,;-6.72,3.16,;-8.05,2.39,;-9.54,2.79,;-9.94,1.31,;-8.45,.91,)| Show InChI InChI=1S/C26H31FN6O2/c1-14(2)22-24(16-8-21(34-3)26-28-13-29-33(26)10-16)31-20-9-19(27)23(32-25(20)22)15-4-6-17(7-5-15)30-18-11-35-12-18/h8-10,13-15,17-18,30-31H,4-7,11-12H2,1-3H3 | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.320 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description HEK-Blue-cells (Invivogen) overexpressing human TLR7, TLR8 or TLR9 receptors were used for screening inhibitors of these receptors using an inducible... |
US Patent US10544143 (2020)
BindingDB Entry DOI: 10.7270/Q2QF8W80 |
More data for this Ligand-Target Pair | |